Hypocrellin B Exerts Its Antitumor Effect on Colorectal Cancer by Inhibiting the AKT Pathway

Area of Science:

• Oncology
• Natural Products Chemistry

Background:

• Colorectal cancer is a leading cause of cancer death globally.
• Advanced colorectal cancer has limited therapeutic strategies.
• The anti-tumor potential of hypocrellin B in colorectal cancer is not well understood.

Purpose of the Study:

• To investigate the anti-cancer effects of hypocrellin B on human colorectal cancer cells.
• To elucidate the molecular mechanisms underlying hypocrellin B's action.
• To evaluate hypocrellin B's efficacy in preclinical models.

Main Methods:

• In vitro studies on colorectal cancer cell lines assessing proliferation, migration, and apoptosis.
• In vivo studies using a mouse xenograft model.
• Analysis of the AKT/STING signaling pathway.

Main Results:

• Hypocrellin B significantly inhibited colorectal cancer cell proliferation and migration.
• Hypocrellin B induced apoptosis in colorectal cancer cells.
• Hypocrellin B demonstrated anti-tumor activity in a mouse xenograft model.
• The compound's mechanism involves targeting the AKT/STING pathway by inhibiting AKT phosphorylation.

Conclusions:

• Hypocrellin B exhibits potent anti-colorectal cancer properties.
• Targeting the AKT/STING pathway is a key mechanism of hypocrellin B's anti-tumor effect.
• Hypocrellin B represents a promising therapeutic candidate for colorectal cancer.